

# 37th National Medicinal Chemistry Symposium

## Confirmed Speakers

### Session 1: Integrating Novel Chemical Modalities in Hit-to-lead: a New Paradigm for Early Drug Discovery

#### Discovery and Development of Macrocyclic Peptides for the Treatment of Complement-Mediated Disorders



Dr Susan ASHWELL  
(RA PHARMA, Cambridge, United States)

#### Impact of Structure Based Drug Design in GPCR Lead Optimisation Strategies



Dr Miles CONGREVE  
(SOSEI HEPTARES, Welwyn Garden City, United Kingdom)

#### Translating RNA Sequence into Lead Small Molecule Medicines



Prof. Matthew DISNEY  
(SCRIPPS RESEARCH INSTITUTE, Jupiter, United States)

#### Structural Approach to Identify Lead Scaffolds for Protein-Protein Interaction Targets



Prof. Kyle HADDEN  
(UNIVERSITY OF CONNECTICUT, Storrs, United States)

#### Title of talk to be confirmed



Dr Nello MAINOLFI  
(KYMERA THERAPEUTICS, Cambridge, United States)

#### Integrating DNA-Encoded Library Technologies in Lead Discovery



Dr Lisa MARCAURELLE  
(GSK, Cambridge, United States)


### Session 2: New Directions in Targeting DNA Damage Repair (DDR)

#### Discovery and Optimization of Novel PARG Inhibitors



Dr Hilary BECK  
(IDEAYA BIOSCIENCES, South San Francisco, United States)

#### Discovery of Potent and Selective DNA-PK Inhibitors via Structure-Guided Virtual Screening Strategies



Dr Charlene FALLAN  
(ASTRAZENECA, Cambridge, United Kingdom)

#### Discovery of DNA Polymerase theta (Pol?) Inhibitors: HTS to in vitro Probes

# 37th National Medicinal Chemistry Symposium

## Confirmed Speakers



Dr Robert HEALD  
(ARTIOS PHARMA LTD, Cambridge, United Kingdom)

### **Damage Incorporated: Discovery of ATR Inhibitor BAY 1895344 with Favorable PK Properties and Promising Anti-Tumor Efficacy in Monotherapy and Combination in Preclinical Tumor Models**



Dr Ulrich LÜCKING  
(BAYER HEALTHCARE, Berlin, Germany)

### **The Modification of Pyrazolopyrimidinones and their Effect on WEE1 Inhibition and the DNA Damage Response**



Assoc. Prof. Phil REIGAN  
(UNIVERSITY OF COLORADO, Aurora, United States)

## **Session 3: Hot Targets from NYC Academic and Biotech Scene**

### **Designing and Combining Cancer's Off Switches**



Dr Karen AKINSANYA  
(SCHRODINGER, New York City, United States)

### **Rational Design of Inhibitors of Protein-Protein Interactions**



Prof. Paramjit ARORA  
(NYU, New York, United States)

### **Next Generation Drug Discovery**



Dr Steve COLLETTI  
(LODO THERAPEUTICS, New York, United States)

### **Optimization of Mycobacterium Tuberculosis (Mtb) Selective Inhibitors of Lipoamide Dehydrogenase (Lpd)**



Dr John GINN  
(TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, New York, United States)

### **Therapeutic Potential of the Gut-Brain Axis**



Dr Ann WEBER  
(KALLYOPE, New York, United States)

## **Session 4: Targeting Autophagy for Cancer, Neurodegeneration, or Autoimmune Disease**

### **The Development of Substrate Competitive and Allosteric Inhibitors of Cysteine Protease ATG4B to Prevent Autophagic Flux**

# 37th National Medicinal Chemistry Symposium

## Confirmed Speakers



Dr Jason CROSS  
(MD ANDERSON CANCER CENTER, Houston, United States)

### Chemical Activation of Chaperone-Mediated Autophagy for Protection against Neurodegeneration



Prof. Evaripidis GAVATHIOTIS  
(ALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, United States)

### Activating PTEN-Induced Kinase 1 (PINK1) for Parkinson's Disease



Dr Nicholas HERTZ  
(MITOKININ, New York, United States)

### Bcl-2 Regulation of Beclin 1-Dependent Autophagy in Health and Disease



Prof. Beth LEVINE  
(UT SOUTHWESTERN MEDICAL CENTER, Dallas, United States)

### Unraveling Autophagy in Cancer Using Chemical Genetics



Prof. Jeff MACKEIGAN  
(MICHIGAN STATE UNIVERSITY, East Lansing, United States)

### Title of talk to be confirmed



Dr Jenny VIKLUND  
(SPRINT BIOSCIENCE, Huddinge, Sweden)

## Session 5: "If At First You Don't Succeed, Try, Try, Try Again": How Clinical Failures Propelled Next Generation Candidates

### 3 Generations of RAF Inhibitors – Learnings and Improvements Based on Clinical Data



Dr Robert AVERSA  
(NOVARTIS, Cambridge, United States)

### Discovery of Oral CGRP Receptor Antagonists for the Treatment of Migraine: Learning from (Clinical) Experience



Dr Chris BURGEY  
(MERCK & CO., INC., Rahway, United States)

### LPA1 Receptor Antagonists for the Treatment of IPF

# 37th National Medicinal Chemistry Symposium

## Confirmed Speakers



Dr Peter CHENG  
(BRISTOL-MYERS SQUIBB, New York, United States)

### Leveraging the Human PK of PF-06882961, an Oral Small Molecule GLP-1R Agonists, in the Discovery of a 2nd Generation Candidate



Dr David GRIFFITH  
(PFIZER, New York, United States)

### Discovery of Risdiplam, a Selective SMN2 Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy



Dr Hasane RATNI  
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)

### Evolution of Clinical PI3K Inhibitors at Genentech



Dr Steve STABEN  
(GENENTECH, South San Francisco, United States)

## Session 6: Lessons from Drug Hunters across Academia, NPOs and the Pharmaceutical Industry

### Discovery of Novel Drug Regimens for the Treatment of Tuberculosis



Dr Christopher B. COOPER  
(TB ALLIANCE, New York, United States)

### Discovery of Upadacitinib: a Tricyclic Janus Kinase 1 (JAK1) Inhibitor



Dr Kristine E. FRANK  
(ABBVIE, North Chicago, United States)

### Discovery of mGlu4 PAMs for the Treatment of Neurological Diseases



Prof. Craig LINDSLEY  
(VANDERBILT UNIVERSITY, Nashville, United States)

### DSM265, a Dihydroorotate Dehydrogenase Inhibitor for the Treatment of Malaria



Prof. Meg PHILLIPS  
(UNIVERSITY OF TEXAS SOUTHWESTERN MED CENTER, Dallas, United States)

### Discovery of the Selective Allosteric TYK2 Inhibitor BMS-986165 for the Treatment of Autoimmune Diseases

# 37th National Medicinal Chemistry Symposium

## Confirmed Speakers

---



Dr Steve WROBLESKI  
(BRISTOL-MYERS SQUIBB, Princeton, United States)

### **Delivering Innovative Medicines: Small Changes can have a Large Effect**



Dr Wendy YOUNG  
(GENENTECH, South San Francisco, United States)